Snibe released its 2026 interim report on August 14, 2026. Total operating revenue was 2.42 billion yuan, net profit attributable to the parent company was 868 million yuan, and net cash inflow from operating activities was 901 million yuan. The latest asset-liability ratio was 8.14 percent, up 1.00 percentage point from the previous quarter and up 0.65 percentage point from the same period last year. The latest gross margin was 70.88 percent, down 2.60 percentage points from the previous quarter. The latest return on equity was 9.67 percent, and diluted earnings per share was 1.11 yuan. The latest total asset turnover was 0.25 times, the latest inventory turnover was 0.67 times, the number of shareholders was 22,200, and the top ten shareholders held 514 million shares, accounting for 65.43 percent of total share capital.
Shenzhen New Industries BiomedicalCompany released interim report with net profit of 868 million yuan, indicating strong financial performance.